Expression of aquaporin-2 in the collecting duct and responses to tolvaptan

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Tolvaptan, a vasopressin type-2 receptor antagonist, is indicated for fluid retention. It is considered that the response to tolvaptan reduces as renal function deteriorates, whereas we sometimes experience "non-responders" to tolvaptan despite well-preserved renal function. While the expression of aquaporin-2 might be a key to response to tolvaptan, detailed mechanism of refractoriness to tolvaptan remains unknown. We experienced two patients with congestive heart failure and diabetic nephropathy, in whom the responses to tolvaptan were uniquely opposite. In one case, immunohistochemical staining showed expression of aquaporin-2 in the collecting duct despite severely reduced renal function, followed by the good response to tolvaptan with increased urine output. In another case, immunohistochemical staining showed absence of aquaporin-2 with infiltration of inflammatory cells in the kidney medulla despite relatively preserved renal function, followed by refractoriness to tolvaptan without any increase in urine output. Inactivated aquaporin-2 expression in the collecting duct, which was for example caused by pre-clinical urinary infection as our latter case, might have an association with refractoriness to tolvaptan.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalCEN case reports
Volume10
Issue number1
DOIs
StatePublished - 2021/02/01

Keywords

  • Arginine vasopressin
  • Diuretics
  • Responder

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Expression of aquaporin-2 in the collecting duct and responses to tolvaptan'. Together they form a unique fingerprint.

Cite this